We believe that Imint will keep growing by signing new deals, extending current agreements to include more features and eventually also succeed in penetrating the low- and midrange segment. We have not performed any greater modifications to our estimates, and our fair value range remains unchanged.
Read more and download the research update: http://bit.ly/2N9woxE
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye – Research Powered Investment Banking. https://www.redeye.se/about/
